Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...

NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the ...

Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

Novartis, a global leader in breast cancer care, today announced the launch of the "Your Attention, Please" campaign, which ...

Novartis (NYSE:NVS) and MSN Pharmaceuticals have reached agreement in a Delaware federal court to dismiss patent litigation ...

In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...

Super Bowl LIX is already proving to offer serious star power, with ad spots led by Chris Pratt, Eugene Levy, Michelle ...

SALES FORECAST: Novartis's sales are forecast at $12.78 billion, according to analysts' estimates compiled by Visible Alpha. This compares with $11.42 billion the year before. Shares rose 5.1% over ...

As Trump appointee and vaccine skeptic RFK Jr. looks toward Washington, Novartis (NVS) CEO Vas Narasimhan is concerned about ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...